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Abstract
Human immunodeficiency virus type 1 (HIV-1) persists in a latent reservoir of infected resting
memory CD4 cells in patients receiving antiretroviral therapy. We assessed whether multitarget
therapy with enfuvirtide, 2 reverse-transcriptase inhibitors, and a ritonavir-boosted protease inhibitor
leads to decay of this reservoir. Nineteen treatment-naive patients initiated this regimen; 9
experienced virologic suppression and continued enfuvirtide-containing therapy for at least 48
weeks. In enfuvirtide-treated patients with virological suppression, there was no decay of the latent
reservoir (95% confidence interval for half-life, 11 months to infinity). The stability of the latent
reservoir despite intensive therapy suggests that new strategies are needed to eradicate HIV-1 from
this reservoir.
Human immunodeficiency virus type 1 (HIV-1) persists as integrated DNA in resting memory
CD4 T cells in patients receiving antiretroviral therapy (ART) [1–3]; this latent reservoir has
an estimated half-life of 44 months [4]. The lack of decay of this latent reservoir may reflect
the intrinsic stability of the virus in resting memory CD4 cells, but it may also be due to ongoing
low-level HIV-1 replication that replenishes the reservoir. Although most patients receiving
standard antiretroviral regimens have low-level viremia detectable with special assays [5],
there is controversy as to whether this residual viremia represents ongoing cycles of HIV-1
replication or episodic release of virus from stable reservoirs (eg, from cellular sources or
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anatomic compartments, such as the central nervous system). If current antiretroviral regimens
completely block viral replication, then more intensive ART will not lead to decay of the latent
reservoir. Alternatively, if ongoing viral replication contributes to maintenance of the latent
reservoir, then increasing the potency of therapy by inhibiting additional viral targets may
further diminish replication and lead to more rapid decay of the latent reservoir. Studies of the
effect of more intensive ART on the size of the latent reservoir may help determine whether
ongoing replication contributes to the stability of the latent pool.
Current first-line antiretroviral regimens inhibit HIV-1 enzymes that function inside the host
cell, such as reverse transcriptase or protease. The antiretroviral activity of combination therapy
with reverse-transcriptase and protease inhibitors may be increased by adding an additional
agent—such as the fusion inhibitor enfuvirtide—that blocks an extracellular target [6].
Inhibition of HIV-1 via an extracellular site of action might also more effectively suppress
replication if efflux pumps or other mechanisms result in cellular sanctuaries of viral
replication. We assessed whether initiation of intensive ART with a multitarget regimen that
includes fusion, protease, and reverse-transcriptase inhibitors leads to decay of the HIV-1 latent
reservoir.
Methods
In a single-arm study (AIDS Clinical Trials Group A5173), treatment-naive HIV-1-infected
patients with CD4 cell counts of ≥ 100 cells/μL, HIV-1 RNA loads of ≥ 1000 copies/mL, and
no drug-resistance mutations (as determined by genotypic testing) initiated therapy with 90
mg of enfuvirtide administered by subcutaneous injection twice daily, 300 mg of tenofovir
disoproxil fumarate administered daily, either 200 mg of emtricitabine or 300 mg of lamivudine
administered daily, 1000 mg of saquinavir mesylate administered twice daily, and 100 mg of
ritonavir administered twice daily. Patients who achieved a viral load of <50 copies/mL and
continued enfuvirtide-containing ART were tested at week 24 and then every 24 weeks for the
frequency of latently infected resting CD4 cells (measured in infectious units per million cells
[IUPM]), using methods described elsewhere [7]; the planned study duration was 96 weeks.
Viral load testing (Roche Amplicor HIV-1 Monitor assay, ultrasensitive version 1.5) was
performed at a central laboratory for samples collected at study entry; on days 4 and 10; at
weeks 4, 8, 12, and 16; and then every 8 weeks until week 96. CD4 cell counts were measured
at entry; on day 10; at weeks 4, 8, 12, and 16; and then every 8 weeks until week 96. CD4 and
CD8 cell activation was assessed at entry and every 24 weeks, by measuring the percentage of
cells that expressed CD38 and by estimating CD38 cell surface density from the mean
fluorescence intensity of this marker. CCR5 density on nonactivated (HLA-DR–negative) CD4
cells was measured at study entry.
We analyzed the latent-reservoir decay rate in patients who attained a viral load of <50 copies/
mL and received enfuvirtide-containing ART for at least 48 weeks (the analysis cohort). On
the basis of previous estimates of assay and biologic variation and the correlation among
repeated observations [8], in the initial study design we estimated that 10 evaluable patients,
each with 4 latent-reservoir measurements, would provide 80% power to detect a change in
the decay rate from the reported value of 44 months to <12 months. The original target
enrollment was 40 patients, with the expectation that some would not attain a viral load of <50
copies/mL and that others would discontinue the study regimen prematurely. Because of both
slow enrollment and data showing no evidence of decline in the latent reservoir, an independent
review committee recommended an early stop to accrual.
The primary analysis of the latent reservoir was based on data from the analysis cohort; the
estimated decay and 95% confidence intervals were obtained from a random-effects model of
log-transformed latent-reservoir measurements [4]. Analyses of toxicities were based on data
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from all patients treated with enfuvirtide. Additional analyses were descriptive and used rank-
based and partial correlations and repeated-measures models. Data from patients in the analysis
cohort were compared with those from other patients by means of Wilcoxon rank sum and
Fisher exact tests.
Results
Nineteen treatment-naive patients initiated intensive ART with enfuvirtide, tenofovir
disoproxil fumarate, either emtricitabine or lamivudine, saquinavir mesylate, and ritonavir.
The median age was 36 years; of the 19 patients, 17 (89%) were male, 11 (58%) were white,
5 (26%) were Hispanic, 2 (11%) were African American, and 1 (5%) was American Indian/
Alaska Native. The median baseline CD4 cell count was 262 cells/μL (range, 146–597), and
the median baseline viral load was 4.8 log10 (63,000) copies/mL.
Seven patients stopped taking enfuvirtide before week 48 (6 because of toxicities related to
injection site reactions [at weeks 1–13] and 1 for personal reasons not related to toxicity); these
7 patients were excluded from the latent-reservoir analysis. Three patients did not experience
virologic suppression or had virologic rebound before week 48 and were excluded from the
reservoir analysis. Nine patients (the analysis cohort) both experienced virologic suppression
and continued enfuvirtide-containing ART for at least 48 weeks. Patients in the analysis cohort
were in general similar to those who discontinued enfuvirtide before week 48 (n = 7) and similar
to those who did not have sustained virologic suppression (n = 3) in terms of age, sex, baseline
CD4 cell count, and viral load, although the power to detect differences was small.
The patients in the analysis cohort had a median CD4 cell count increase at week 48 of 443
cells/μL, compared with 228 cells/μL in 6 patients who had a viral load of <50 copies/mL at
week 48 but were no longer receiving enfuvirtide (P = .08). The median time to achieving a
viral load of <50 copies/mL in the analysis cohort was 16 weeks; patients who did not remain
on enfuvirtide had a similar median time to achieving an undetectable viral load (also 16
weeks).
Patients in the analysis cohort had a median of 4 latent-reservoir measurements each. Four
patients had a slight decrease of the number of latently infected cells, and 5 patients had a slight
increase (Figure 1). Overall, there was no evidence for decay of the latent reservoir (95%
confidence interval for half-life, 11 months to infinity). The latent-reservoir decay rate
observed in this trial was similar to that seen in previous studies in which patients were given
less intensive antiretroviral regimens but on average were virologically suppressed for longer
periods of time [4] (Figure 1).
We examined the relationship between baseline factors and the latent reservoir. Latent-
reservoir size (measured by the mean log10 IUPM) was inversely correlated with baseline CD4
cell count (r = −0.77; P = .016) (Figure 2); that is, the lower the baseline CD4 cell count, the
larger the mean log10 IUPM. This association persisted after adjustment for baseline viral load.
After adjusting for baseline CD4 cell count, there was no relationship between baseline viral
load and log10 IUPM (r = 0.36; P = .38). There was no evidence for an association between
mean log10 IUPM and each of the following baseline factors: age, CCR5 density on CD4 cells,
and CD4 or CD8 cell activation (measured by the percentage of T cells expressing CD38 and
CD38 density) (r = −0.40 to 0.14; all P values are <.30).
We also evaluated the relationship between latent-reservoir size and immune activation during
ART. Although in the analysis cohort log10 IUPM was inversely correlated with CD38 density
on CD4 and CD8 cells at the time of latent-reservoir measurement (r = −0.4 and −0.24,
respectively; P< .05), these associations were no longer statistically significant after
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adjustment for baseline CD4 cell count. There was also no statistically significant correlation
between latent-reservoir size and the percentage of CD4 or CD8 cells expressing CD38.
To assess whether enfuvirtide use affected immune activation, we compared the percentage of
T cells expressing CD38 and CD38 density of patients who continued to receive the fusion
inhibitor with those of patients who stopped receiving the drug before the study was completed.
Among patients with a viral load of <50 copies/mL, there was no evidence for a difference in
immune activation at week 48 between those in the analysis cohort (who continued receiving
enfuvirtide; n = 9) and those who had discontinued enfuvirtide (n = 5) before this time point.
Similar results were seen at weeks 24, 72, and 96.
Finally, because CCR5 density on CD4 cells has been associated with in vitro activity of
enfuvirtide [9] and response to ART [10], we hypothesized that lower CCR5 density might be
associated with greater enfuvirtide activity. To test this hypothesis, we examined whether
CCR5 cell surface levels affected how rapidly viral load declined after initiation of enfuvirtide-
containing therapy. The estimated mean change in viral load from day 0 to day 7 was −1.26
log10 copies/mL (n = 18). There was no association (r = −0.13; P = .6) between baseline CCR5
density and change in viral load from day 0 to day 7 (range of days on which the viral load was
measured, days 4–10).
Discussion
In treatment-naive HIV-1-infected patients who received enfuvirtide-containing multitarget
ART and who achieved and sustained a plasma viral load of <50 copies/mL, we did not detect
a decline in latent-reservoir size over 96 weeks. Although the small sample size limits our
power to detect associations—particularly in the secondary analyses—we can, with 95%
certainty, exclude the possibility that the half-life of the latent reservoir is <11 months in
patients receiving this intensive regimen. Our trial examined the latent-reservoir decay rate in
treatment-naive patients who initiated their first antiretroviral regimen, whereas most previous
studies measured the reservoir in patients who were already receiving therapy. Despite this
difference, the latent-reservoir decay rate observed in our trial was similar to that seen in a
study of patients receiving less intensive ART regimens (Figure 1), which were generally
combinations of nucleoside reverse-transcriptase inhibitors with nonnucleoside reverse-
transcriptase inhibitors or protease inhibitors [4]. Our results suggest that addition of a fusion
inhibitor to a regimen that includes reverse-transcriptase and protease inhibitors does not
dramatically affect the rate of latent-reservoir decay.
Are there factors that influence the size of the latent reservoir that might impact the ability to
deplete this pool? We found that baseline CD4 cell count was inversely associated with the
size of the latent reservoir, even after adjustment for baseline viral load. This observation is
consistent with the hypothesis that a longer duration of uncontrolled viremia—which leads to
more extensive CD4 cell count decline—might result in a larger latent reservoir. However, the
latent reservoir is established during acute HIV-1 infection and persists even in patients who
initiate therapy during this period [11,12]. Alternatively, the latent reservoir may be smaller in
patients with more robust immune systems. Whether earlier initiation of ART in patients with
chronic HIV-1 infection might result in a smaller latent reservoir is not known. The finding of
an inverse relationship between baseline CD4 cell count and latent-reservoir size must be
confirmed in larger study populations.
Is the size of the latent reservoir related to the amount of persistent immune activation? After
adjusting for baseline CD4 cell count, we did not observe any association between T cell
activation and latent-reservoir size. We also did not find evidence that use of enfuvirtide had
Gandhi et al. Page 4













an effect on immune activation in those patients whose viral load was <50 copies/mL, although
the power to detect differences was small.
There are several implications of our study. The stability of the latent reservoir in patients
initiating therapy with a multitarget regimen that includes fusion, protease, and reverse-
transcriptase inhibitors suggests that this strategy will not lead to depletion of this reservoir,
an important step toward eradication of HIV-1 infection. It remains to be seen whether
intensification of therapy with agents that have other mechanisms of action—such as integrase
inhibitors or CCR5 antagonists—will impact residual viremia or the latent reservoir; studies
are ongoing. If persistent viral replication does not contribute to maintenance of the latent
reservoir [13], then novel strategies— such as reactivation of latent HIV-1 provirus or
acceleration of the death rate of latently infected cells [14,15]—may be needed to successfully
eradicate HIV-1 infection. Studies of new approaches must be urgently pursued.
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Latent reservoir in human immunodeficiency virus type 1 (HIV-1)–infected patients receiving
intensive enfuvirtide-containing anti-retroviral therapy (ART) who had sustained virologic
suppression and remained on enfuvirtide for at least 48 weeks (solid lines). The 95% confidence
interval for the half-life of the latent reservoir is 11 months to infinity. Dashed lines represent
the mean decay slope and 95% confidence intervals from measurements of the latent reservoir
in 62 patients who were on ART regimens that did not contain enfuvirtide (historical controls)
[4]. IUPM, infectious units per million cells.
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Inverse correlation between the mean latent-reservoir size and baseline CD4 cell count in
human immunodeficiency virus type 1 (HIV-1)–infected patients in the analysis cohort. IUPM,
infectious units per million cells.
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